2023
Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer
Ahmad M, Saeed S, Olamiju B, Silber A, Leventhal J. Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer. International Journal Of Women's Dermatology 2023, 9: e073. PMID: 36733315, PMCID: PMC9886509, DOI: 10.1097/jw9.0000000000000073.Peer-Reviewed Original ResearchDermatologic toxicitiesSOC patientsBreast cancerEducational interventionFurther multi-institutional studiesCancer treatmentMulti-institutional studyAfrican American/BlackDermatologic effectsInfusion centerAmerican/BlackPatient educationMinority patientsColor patientsEducational pamphletChemotherapyPatientsLarger sample sizeMedical careSkin typePilot studyHigh school degreeSmall sample sizeSample sizeMost participants
2003
Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management
Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management. Clinical Lung Cancer 2003, 4: 366-369. PMID: 14599302, DOI: 10.3816/clc.2003.n.016.Peer-Reviewed Original ResearchDermatologic effectsGefitinib treatmentClinical trialsDry skinSide effectsFrequent drug-related adverse effectsDrug-related allergic reactionsRecent phase II trialDrug-related adverse effectsAdverse effectsDermatologic adverse effectsPhase II trialDermatologic side effectsCell lung cancerNumerous clinical trialsSimilar side effectsVariety of treatmentsMechanism of actionAcneiform rashTopical clindamycinAdvanced NSCLCEpidermal growth factor receptor tyrosine kinaseII trialMost patientsGefitinib therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply